These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A possible role for intermediate lobe peptides in the pathogenesis of idiopathic aldosteronism. Mulrow PJ Trans Am Clin Climatol Assoc; 1984; 95():26-33. PubMed ID: 6089399 [No Abstract] [Full Text] [Related]
3. Pro-opio(melano)cortin and brain homeostasis. De Wied D Prog Brain Res; 1982; 55():473-82. PubMed ID: 6298866 [No Abstract] [Full Text] [Related]
4. Effect of N-terminal portion of pro-opiomelanocortin on aldosterone release by human adrenal adenoma in vitro. Lis M; Hamet P; Gutkowska J; Maurice G; Seidah NG; Larivière N; Chrétien M; Genest J J Clin Endocrinol Metab; 1981 Jun; 52(6):1053-6. PubMed ID: 6262359 [TBL] [Abstract][Full Text] [Related]
7. [Adrenocorticotropic hormone and its peptide derivatives]. Zdrojewicz Z Wiad Lek; 1987 Mar; 40(6):387-92. PubMed ID: 2820155 [No Abstract] [Full Text] [Related]
8. Measurement of N-terminal (1-76) of human proopiomelanocortin in human plasma: correlation with adrenocorticotropin. Chan JS; Seidah NG; Chrétien M J Clin Endocrinol Metab; 1983 Apr; 56(4):791-6. PubMed ID: 6300165 [No Abstract] [Full Text] [Related]
10. Electrophysiological effects of peptides derived from pro-opiomelanocortin. Urban IJ Pharmacol Ther; 1984; 24(1):57-90. PubMed ID: 6328550 [No Abstract] [Full Text] [Related]
11. An aldosterone stimulating agent: a novel human pituitary hormone from pro-opiomelanocortin. Chrétien M; Larivière N; Lis M; Gutkowska J; Hamet P; Genest J; Seidah NG Trans Assoc Am Physicians; 1981; 94():225-35. PubMed ID: 7344222 [No Abstract] [Full Text] [Related]
12. Natriuretic and hypertensinogenic pro-opiomelanocortin derived peptides. Gruber KA; Callahan MF; Kirby RF; Johnson AK; Lymangrover JR Regul Pept Suppl; 1985; 4():118-23. PubMed ID: 2997849 [No Abstract] [Full Text] [Related]
13. Response of human aldosteronoma cells in culture to the N-terminal glycopeptide of pro-opiomelanocortin and gamma 3-MSH. Schiffrin EL; Chrétien M; Seidah NG; Lis M; Gutkowska J; Cantin M; Genest J Horm Metab Res; 1983 Apr; 15(4):181-4. PubMed ID: 6862354 [TBL] [Abstract][Full Text] [Related]
14. [Biologically active fragments of protein hormones]. Iudaev NA; Pankov IuA; Babichev VN; Fedotov VP; Shvachkin IuP Vopr Med Khim; 1984; 30(3):8-15. PubMed ID: 6089433 [TBL] [Abstract][Full Text] [Related]
15. The human behavioral pharmacology of the common core heptapeptides. Branconnier RJ Pharmacol Ther; 1981; 14(2):161-75. PubMed ID: 6273945 [No Abstract] [Full Text] [Related]
16. New perspectives in neuropeptides. Biosynthesis from large precursors. The pro-opio-melanocortin model in the pars intermedia. Chrétien M; Gossard F; Crine P; Gianoulakis C; Seidah NG Acta Psychiatr Belg; 1980; 80(5):699-713. PubMed ID: 6263051 [TBL] [Abstract][Full Text] [Related]
18. N-terminal peptide of pro-opiomelanocortin in human amniotic fluid. Lis M; Julesz J; Senicas VM; Hamilton E; Perry T; Hermann K; Heinrich D Am J Obstet Gynecol; 1983 Jul; 146(5):575-9. PubMed ID: 6305197 [TBL] [Abstract][Full Text] [Related]
19. Effects of pro-opiomelanocortin-derived peptides on plasma levels of glucagon, insulin and glucose. Knudtzon J Horm Metab Res; 1986 Sep; 18(9):579-83. PubMed ID: 3023222 [TBL] [Abstract][Full Text] [Related]
20. The potential of melanotropins in the treatment of nervous system diseases. Gispen WH Ann N Y Acad Sci; 1993 May; 680():401-11. PubMed ID: 8390160 [No Abstract] [Full Text] [Related] [Next] [New Search]